📊 BCDA Key Takeaways
Is BioCardia, Inc. (BCDA) a Good Investment?
BioCardia is a pre-revenue or early-stage biotech company burning significant cash with zero revenue generation, indicating failed commercialization or product launch delays. With -$4.9M operating cash flow, -$6.2M net loss, and only $5.3M cash on hand, the company faces a critical runway crisis of approximately 12-14 months at current burn rates. Without immediate revenue generation or successful capital raises, insolvency is a material risk.
BioCardia's fundamentals are very weak: revenue has effectively collapsed to zero while operating and net losses remain large relative to its asset and equity base. The company does have meaningful cash and no long-term debt, but current cash burn and deeply negative returns on assets and equity indicate a fragile financial position unless commercialization or funding improves materially.
Why Buy BioCardia, Inc. Stock? BCDA Key Strengths
- Adequate liquidity ratio of 1.62x suggests short-term bills can be covered
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Cash position of $5.3M provides near-term operational runway
- Cash balance of $5.29M provides near-term operating flexibility
- No meaningful long-term debt reduces financial leverage risk
- Current and quick ratios of 1.62x indicate acceptable short-term liquidity for now
BCDA Stock Risks: BioCardia, Inc. Investment Risks
- Complete revenue collapse (87.8% YoY decline to $0.00) indicates failed product commercialization or severe market rejection
- Negative operating cash flow of -$4.9M combined with minimal cash reserves creates acute insolvency risk within 12-14 months
- Negative ROE of -237.7% and ROA of -101.6% demonstrate severe value destruction and capital inefficiency
- Operating losses of -$6.3M with no revenue pathway suggests fundamental business model failure
- Gross profit of $107K with zero revenue is unexplained and raises data quality concerns
- Revenue fell 87.8% year over year to effectively zero, raising major concerns about business viability and commercialization progress
- Operating cash flow of -$4.94M and net loss of -$6.24M imply continued heavy cash burn
- ROE of -237.7% and ROA of -101.6% show severe capital inefficiency and weak underlying economics
Key Metrics to Watch
- Cash runway and monthly burn rate trends
- Revenue recognition from any commercial or regulatory approvals
- Capital raise announcements or debt financing activity
- Clinical trial progress and regulatory status updates
- Quarterly revenue recovery and consistency of commercial or partnership income
- Cash runway based on operating cash burn versus ending cash balance
BioCardia, Inc. (BCDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
BioCardia, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BCDA Profit Margin, ROE & Profitability Analysis
BCDA vs Healthcare Sector: How BioCardia, Inc. Compares
How BioCardia, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioCardia, Inc. Stock Overvalued? BCDA Valuation Analysis 2026
Based on fundamental analysis, BioCardia, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioCardia, Inc. Balance Sheet: BCDA Debt, Cash & Liquidity
BCDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioCardia, Inc.'s revenue has declined by 94% over the 5-year period, indicating business contraction. The most recent EPS of $-2.90 indicates the company is currently unprofitable.
BCDA Revenue Growth, EPS Growth & YoY Performance
BCDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.5M | $-0.24 |
| Q2 2025 | N/A | -$1.6M | $-0.40 |
| Q1 2025 | N/A | -$2.3M | $-0.59 |
| Q3 2024 | N/A | -$1.6M | $-0.61 |
| Q2 2024 | $3.0K | -$1.6M | $-0.88 |
| Q1 2024 | $55.0K | -$2.3M | $-0.09 |
| Q3 2023 | $212.0K | -$2.5M | $-0.12 |
| Q2 2023 | $43.0K | -$2.5M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioCardia, Inc. Dividends, Buybacks & Capital Allocation
BCDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioCardia, Inc. (CIK: 0000925741)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BCDA
What is the AI rating for BCDA?
BioCardia, Inc. (BCDA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BCDA's key strengths?
Claude: Adequate liquidity ratio of 1.62x suggests short-term bills can be covered. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk. ChatGPT: Cash balance of $5.29M provides near-term operating flexibility. No meaningful long-term debt reduces financial leverage risk.
What are the risks of investing in BCDA?
Claude: Complete revenue collapse (87.8% YoY decline to $0.00) indicates failed product commercialization or severe market rejection. Negative operating cash flow of -$4.9M combined with minimal cash reserves creates acute insolvency risk within 12-14 months. ChatGPT: Revenue fell 87.8% year over year to effectively zero, raising major concerns about business viability and commercialization progress. Operating cash flow of -$4.94M and net loss of -$6.24M imply continued heavy cash burn.
What is BCDA's revenue and growth?
BioCardia, Inc. reported revenue of $0.0.
Does BCDA pay dividends?
BioCardia, Inc. does not currently pay dividends.
Where can I find BCDA SEC filings?
Official SEC filings for BioCardia, Inc. (CIK: 0000925741) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BCDA's EPS?
BioCardia, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BCDA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioCardia, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BCDA stock overvalued or undervalued?
Valuation metrics for BCDA: ROE of -237.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BCDA stock in 2026?
Our dual AI analysis gives BioCardia, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BCDA's free cash flow?
BioCardia, Inc.'s operating cash flow is $-4.9M, with capital expenditures of $1.0K.
How does BCDA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -237.7% (avg: 15%), current ratio 1.62 (avg: 2).